Every dated change on the records linked to Enteropathy-associated T-cell lymphoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
The diagnosis is often made on bowel resected as an emergency for perforation or obstruction. Where there is time, it is made at endoscopy with biopsies of the small bowel. Coeliac disease is confirmed or newly diagnosed at the same time, and the rest of the family is offered testing. Staging uses the gastrointestinal system that counts depth and node involvement, and imaging of the whole abdomen matters because disease is often multifocal.
The International Consensus Classification lists type II refractory coeliac disease as a provisional entity; WHO-HAEM5 does not list it separately.
In the population-based series from northern England and Scotland, the 54 patients diagnosed between 1994 and 1998, of whom 35 had chemotherapy (mostly anthracycline-based) with or without surgery and 19 had surgery alone, had a median progression-free survival of 3.4 months and overall survival of 7.1 months. From 1998 the same group gave patients fit enough for it ifosfamide, etoposide and epirubicin alternating with methotrexate, followed by an autologous stem cell transplant; in 26 patients treated that way, five-year progression-free survival was 52 per cent and overall survival 60 per cent. That is a comparison against a historical group from the same region rather than a randomised trial; a 2026 paper summarises the later prospective United Kingdom phase 2 study of the approach as showing more modest outcomes, with one-year survival of 45 per cent. NCI PDQ calls the evidence for transplant consolidation anecdotal. A clinical trial is a reasonable first choice.
Among 54 patients identified in northern England and Scotland, incidence was 0.14 per 100,000 a year and, with chemotherapy in 35 and surgery alone in 19, median progression-free survival was 3.4 months and overall survival 7.1 months; 26 patients given ifosfamide, etoposide and epirubicin with methotrexate followed by autologous transplant had five-year progression-free survival of 52 per cent and overall survival of 60 per cent.